Merck reports positive results form Chinese Phase III TAILOR trial of Erbitux-Folfox combination
Merck has reported that the Chinese Phase III TAILOR study has demonstrated positive results of Erbitux (cetuximab) plus Folfox chemotherapy, compared with Folfox alone in patients with RAS wild-type metastatic colorectal cancer (mCRC).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | Chemotherapy | Colorectal Cancer | Erbitux | Merck | Pharmaceuticals | Study